OR-USB-IF
27.5.2021 00:02:07 CEST | Business Wire | Press release
The USB Promoter Group today announced the release of the USB Power Delivery (USB PD) Revision 3.1 specification, a major update to enable delivering up to 240W of power over the USB Type-C® cable and connector. Prior to this update, USB PD was limited to 100W via a solution based on 20V using USB Type-C cables rated at 5A. The USB Type-C specification has also been updated with Release 2.1 to define 240W cable requirements, and with the updated USB PD protocol and power supply definition, this extends the applicability of USB PD to a large number of applications where 100W wasn’t adequate.
The new USB PD architecture defines a much more stringent power negotiation protocol that helps to ensure that access to and use of this higher power capability can be done safely. It should be noted that safety requirements for products that use power in the range of 100 – 240W are also more stringent than lower power products and are defined by the applicable safety specifications dictated by the regulations for each country where the products will be sold.
“With the new capabilities of USB Power Delivery 3.1, we now enable higher power products such as larger notebook PCs to shift from traditional power connectors to USB Type-C,” said Brad Saunders, USB Promoter Group Chairman. “We also anticipate a wider range of product application developers outside of the traditional USB ecosystem to now consider standardizing on USB Type-C with USB PD power their power needs.”
Key characteristics of the USB PD 3.1 specification include:
- A choice of three new fixed voltages: 28V (above 100W), 36V (above 140W) and 48V (above 180W) joining previously defined 5V, 9V, 15V and 20V fixed voltages.
- A new adjustable voltage mode enabling a range from 15V to one of three maximum voltages (28V, 36V, or 48V) depending on the available power allowing the device being powered to request specific voltages to a 100 mV resolution.
USB Developer Days 2021, in the second half of this year, will include detailed technical training covering the updated USB PD and USB Type-C specifications.
This update is part of the USB performance roadmap and is specifically targeted to developers at this time. Branding and marketing guidelines are being established and will include a new cable labeling solution to inform users of the power capability supported by Certified USB Type-C cables.
“Always responsive to the market’s need for a higher-power, truly universal bus connector, the USB Promoter Group has again been quick to recognize and adapt its specifications for charging capability to anticipate customer requirements, potentially creating new markets for USB Power Delivery. ST, as an active member of the USB Promoter Group, with its strong company legacy of cooperation, technical expertise, and product reliability, will continue to provide high-quality, optimized semiconductor solutions,” said Matteo Lo-Presti, Executive Vice President, Analog, Sub-Group General Manager, Analog MEMS, and Sensors Group, STMicroelectronics.
“The 3.1 revision to the USB Power Delivery specification, which includes the capability to provide up to 48 V and 240 W of power, will help enable additional design opportunities for current and new users of USB Type-C technology,” said Deric Waters, senior member of technical staff at Texas Instruments.
About the USB Promoter Group
The USB Promoter Group, comprised of Apple Inc., Hewlett-Packard Inc., Intel Corporation, Microsoft Corporation, Renesas Electronics Corporation, STMicroelectronics, and Texas Instruments, continues to develop the USB family of specifications to meet the market needs for increased functionality and performance of USB solutions. Additionally, the USB Promoter Group develops specification addendums (USB Power Delivery, USB Type-C®, and others) to extend or adapt its specifications to support more platform types or use cases where adopting USB technology will be beneficial in delivering a more ubiquitous, richer user experience.
About the USB-IF
The non-profit USB Implementers Forum, Inc. was formed to provide a support organization and forum for the advancement and adoption of USB technology as defined in the USB specifications. The USB-IF facilitates the development of high-quality compatible USB devices through its logo and compliance program, and promotes the benefits of USB and the quality of products that have passed compliance testing. Further information, including postings of the most recent product and technology announcements, is available by visiting the USB-IF website at www.usb.org .
USB Type-C® and USB-C® are registered trademarks of USB Implementers Forum.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526006131/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom